Morgan Stanley assumed coverage of Zimmer Biomet (ZBH) with an Equal Weight rating and a price target of $115, down from $122. The firm says Zimmer has “decent product cycles,” but argues that the current valuation is “largely appropriate.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet receives FDA approval for Oxford Cementless Partial Knee
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Zimmer Biomet announces CE Mark certification for knee system
- Zimmer Biomet names Arnold Schwarzenegger as Chief Movement Officer
- Zimmer Biomet price target raised to $125 from $120 at RBC Capital